10-Q: Surmodics Reports Q2 2024 Results: Revenue Growth Driven by Medical Device Sales

Surmodics saw a significant increase in revenue in the second quarter of 2024, primarily driven by growth in its Medical Device segment, particularly from the commercial launch of its SurVeil drug-coated balloon.

Summary

• Surmodics reported a 20% increase in total revenue for the first six months of fiscal year 2024, reaching $62.5 million, compared to $52.1 million in the same period of the previous year.
• The Medical Device segment experienced a 25% revenue increase, totaling $48.4 million for the first six months of fiscal 2024, driven by a 41% increase in product sales.
• Product sales in the Medical Device segment were boosted by the initial stocking order and subsequent orders for the SurVeil drug-coated balloon (DCB) from Abbott, as well as continued growth in sales of the Pounce thrombectomy device platform.
• Performance coating royalties and license fee revenue in the Medical Device segment increased by 19% to $18.5 million for the first six months of fiscal 2024.
• The In Vitro Diagnostics (IVD) segment saw a 5% revenue increase, reaching $14.1 million for the first six months of fiscal 2024, with product sales increasing by 4%.
• The company's net loss for the first six months of fiscal 2024 was $0.5 million, an improvement compared to a net loss of $15.6 million in the same period of the previous year.
• Cash used in operating activities was $1.4 million for the first six months of fiscal 2024, a significant decrease from $16.6 million used in the same period of the previous year.
• The company's cash and cash equivalents and available-for-sale investments totaled $40.9 million as of March 31, 2024.

Sentiment

Score: 7

Explanation: The document shows a positive trend with strong revenue growth and improved profitability, but there are still some challenges with gross margins and the company is still reporting a net loss. The commercial launch of new products is a positive sign for future growth.

Positives

• The company experienced strong revenue growth, particularly in the Medical Device segment, driven by the commercial launch of the SurVeil DCB and the Pounce thrombectomy platform.
• The company's net loss significantly improved compared to the previous year.
• Cash used in operating activities decreased substantially, indicating improved operational efficiency.
• The company successfully launched two new thrombectomy products, the Pounce LP and Pounce Venous systems.
• The company has a strong cash position with $40.9 million in cash and investments.

Negatives

• Product gross margins decreased due to increased sales of vascular intervention medical devices, which have lower margins.
• SurVeil DCB license fee revenue declined due to lower clinical trial costs.
• IVD product sales decreased by 6% in the second quarter of fiscal 2024 compared to the prior-year quarter.
• The company is still experiencing a net loss, although it is significantly reduced.

Risks

• The company's reliance on a small number of significant customers, including Abbott and Medtronic, could impact financial results.
• The company's ability to successfully manufacture the SurVeil DCB at commercial volumes is critical.
• The company's ability to obtain and maintain regulatory approvals for its products is essential.
• The company's ability to successfully commercialize its vascular intervention products through its direct salesforce is important.
• The company's ability to comply with the terms of its secured credit facility is necessary.
• The company is exposed to increasing Euro currency risk with respect to its manufacturing operations in Ireland.

Future Outlook

The company anticipates an increase in SG&A expenditures and capital expenditures in fiscal 2024, while R&D expenses are expected to remain significant. The company believes its existing cash and credit facilities will provide sufficient liquidity for fiscal 2024. Long-term cash requirements will depend on the market acceptance of its medical device products and the level of investment in commercialization.

Management Comments

• Management believes the strategy of developing its own medical device products has increased, and will continue to increase, its relevance in the medical device industry.
• Management believes the ease of use, intuitive design, and performance of its thrombectomy systems make these products attractive first-line treatment options for interventionalists.

Industry Context

The company's focus on vascular intervention medical devices aligns with the growing demand for minimally invasive treatments for peripheral arterial disease. The commercial launch of the SurVeil DCB and the Pounce thrombectomy systems positions the company to capitalize on these market trends. The company's performance coating technologies also remain relevant in the broader medical device industry.

Comparison to Industry Standards

• Surmodics' revenue growth of 20% year-over-year is strong compared to the overall medical device industry, which typically sees single-digit growth.
• The company's focus on proprietary technologies and products, such as the SurVeil DCB and Pounce thrombectomy systems, differentiates it from competitors who may rely more on licensing or distribution agreements.
• The company's gross margin of 56.9% for the first six months of fiscal 2024 is lower than some established medical device companies, but this is due to the early stage of commercialization of its vascular intervention products.
• Companies like Medtronic and Abbott, which are also customers of Surmodics, are major players in the medical device industry and serve as benchmarks for market reach and product development.
• Surmodics' investment in R&D, while decreasing, is still significant and is comparable to other companies focused on innovation in the medical device space.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and revenue growth.
• Employees may see increased job security and opportunities due to the company's growth.
• Customers will have access to new and innovative medical devices.
• Suppliers may see increased demand for their products and services.
• Creditors will have increased confidence in the company's ability to repay its debts.

Next Steps

• The company will continue to manufacture and ship commercial units of the SurVeil DCB to Abbott.
• The company will continue to advance the commercialization of its Pounce thrombectomy and Sublime radial access product platforms.
• The company will continue to evaluate its strategy for further clinical investment in the Sundance DCB.
• The company will continue limited market evaluations of its Sublime microcatheters.

Key Dates

Keywords

Medical Devices, Drug-Coated Balloon, Thrombectomy, Vascular Intervention, In Vitro Diagnostics, Performance Coatings, Revenue Growth, Financial Results, SurVeil DCB, Pounce Thrombectomy, Abbott, FDA Approval